{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:35:30Z","timestamp":1768473330267,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":11534,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1981,8,9]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> The effects of single oral doses of nabilone, a synthetic cannabinoid, were studied in eight anxious volunteer subjects. Each subject had two exposures to placebo and three dose levels of nabilone at one\u2010week intervals in a single\u2010blind balanced Latin\u2010square design after the nabilone dose range was determined by each subject's response to a test dose. Heart rate and blood pressure were monitored. The Profile of Mood States (POMS), a self\u2010rating adjective checklist, was used as the quantitative measure of subjective effects. Four subjects performed a continuous avoidance procedure. High doses (4 or 5 mg) of nabilone produced orthostatic hypotension in these subjects. Mild dose\u2010related increases in heart rate also occurred. Despite the occurrence of highly significant levels of sedation, there were no significant effects of nabilone on the continuous avoidance procedure. Two of these four subjects experienced an antianxiety effect from low (1 or 2 mg) nabilone doses. Four other subjects received comparatively lower doses of nabilone and performed on three behavioral tasks at intervals before and after drug: a recognition memory procedure, a task requiring spaced responding at a controlled rate, and a reaction time task. In these subjects there were no reliable effects on blood pressure or heart rate, no significant subjective effects on the POMS, and no antianxiety effects. Drug effects were also minimal on the three behavioral tasks.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1981.tb02618.x","type":"journal-article","created":{"date-parts":[[2013,3,9]],"date-time":"2013-03-09T01:35:12Z","timestamp":1362792912000},"source":"Crossref","is-referenced-by-count":30,"title":["Single\u2010Dose Study of Nabilone in Anxious Volunteers"],"prefix":"10.1002","volume":"21","author":[{"given":"RICHARD M.","family":"GLASS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. H.","family":"UHLENHUTH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FRANK W.","family":"HARTEL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHARLES R.","family":"SCHUSTER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARIAN W.","family":"FISCHMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Psychopharmacology: A Generation of Progress.","author":"Harris LS","year":"1978"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja01062a046"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00730a036"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00429414"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1973.01750330041007"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196896783"},{"key":"e_1_2_1_8_2","first-page":"210","article-title":"Preclinical pharmacologic profile of a psychoactive cannabinoid","volume":"17","author":"Stark P","year":"1975","journal-title":"Pharmacologist."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197722185"},{"key":"e_1_2_1_10_2","volume-title":"Nabilone, An Investigational New Drug.","author":"Eli Lilly and Company.","year":"1975"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1975186720"},{"key":"e_1_2_1_12_2","first-page":"230","article-title":"Antiemetic activity of nabilone, a cannabinol derivative, reversed by naloxone in awake cats","volume":"19","author":"McCarthy LE","year":"1977","journal-title":"Pharmacologist."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197906073002302"},{"key":"e_1_2_1_14_2","first-page":"89","article-title":"Symptomatic volunteers: another patient dimension for clinical trials","volume":"13","author":"Brauzer B","year":"1973","journal-title":"J Clin Pharmacol."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000395070"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/bs.3830190102"},{"key":"e_1_2_1_17_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association.","year":"1968"},{"key":"e_1_2_1_18_2","unstructured":"SpitzerRL EndicottJ RobinsE.Research diagnostic criteria for a selected group of functional disorders 2nd ed.1975(mimeographed booklet)."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-196901000-00010"},{"key":"e_1_2_1_20_2","volume-title":"Eysenck Personality Inventory.","author":"Eysenck HJ","year":"1968"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1037\/h0047161"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760090020004"},{"key":"e_1_2_1_23_2","first-page":"536","article-title":"Compatibility, acquiescence and drug effects","volume":"5","author":"McNair DM","year":"1967","journal-title":"Neuropsychopharmacology."},{"key":"e_1_2_1_24_2","volume-title":"Non\u2010specific Factors in Drug Therapy.","author":"McNair DM","year":"1968"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1037\/h0028329"},{"key":"e_1_2_1_26_2","first-page":"149","article-title":"Experimental designs balanced for the estimation of residual effects of treatments","volume":"2","author":"Williams EJ","year":"1949","journal-title":"Austral J Sci Res."},{"key":"e_1_2_1_27_2","volume-title":"Profile of Mood States.","author":"McNair DM","year":"1971"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(63)90001-3"},{"key":"e_1_2_1_29_2","volume-title":"Predictability in Psychopharmacology: Preclinical and Clinical Correlations.","author":"Uhlenhuth EH","year":"1975"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431981"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(76)90184-2"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.134.6.659"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.153.3736.652"},{"key":"e_1_2_1_34_2","volume-title":"Psychopharmacology: A Generation of Progress.","author":"Meyer RE","year":"1978"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197823154"},{"key":"e_1_2_1_36_2","first-page":"161","article-title":"Nabilone, a cannabinoid, in the treatment of anxiety: an open label and double\u2010blind study","volume":"24","author":"Fabre LF","year":"1978","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_37_2","first-page":"619","article-title":"Nabilone, a cannabinol derivative, in anxiety neurosis","volume":"37","author":"Ilaria RL","year":"1978","journal-title":"Fed Proc."},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770280087009"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1981.tb02618.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1981.tb02618.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:50:00Z","timestamp":1694584200000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1981.tb02618.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,8,9]]},"references-count":37,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1981,8,9]]}},"alternative-id":["10.1002\/j.1552-4604.1981.tb02618.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1981.tb02618.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,8,9]]}}}